IHL - INCANNEX - HOLDERS RESEARCH, page-1064

Correct since the CR raise of last December 2022 and the famous slide 26 of the CR Presentation.
What opportunity has popped up since then?

TGA approval for MDMA & Psilocybin. (Out of left field - no one was anticipating that)
As you would expect and as you have said the BOD grabbed the bull by the horns!

March 16th actually
https://stocknessmonster.com/announcements/ihl.asx-3A614978/

Let's run with this! We already have the experts with Monash and our PSI-GAD program, I bet was the thinking.
(They had this one on the radar anyway ie Ketamine)

Maybe the BOD had to make some re-alignment of priorities!
Income-producing Clinics within 6 months or
our TBI pipeline (IHL-216A) which was going to need a lot of capital for a trial to be conducted within the confines of Public Hospitals.

As you said, we follow the path of least resistance that's what transformational companies do...

Good luck @kingkev

All imo - DYOR - Do not rely on any posts on HC